Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;35(2):168-74.
doi: 10.4103/0974-8520.146236.

Efficacy of Varunadi Ghritha (polyherbal compound) in treated head and neck cancer cases as a biological response modifier

Divya Ravindran  1 , Indhu Hariharan  2 , Richard Muwonge  3 , Rejnish R Kumar  1 , M Radhakrishna Pillai  2 , Kunnambath Ramadas  1
Affiliations

Efficacy of Varunadi Ghritha (polyherbal compound) in treated head and neck cancer cases as a biological response modifier

Divya Ravindran et al. Ayu. 2014 Apr.

Abstract

Background: Persistent immune suppression is reported in Head and Neck Cancers (HNC) even after treatment and a higher recurrence rate was observed in patients with poor CD3 count. Loco regional recurrences and second primary tumours are the common forms of failure in head and neck cancers. Several agents have been tried to overcome this problem without much benefit. In Ayurveda, several plant based products have been reported to have anti-tumour and immunomodulatory properties.

Aim: To test the role of Varunadi Ghritha, as an immunomodulator in apparently healthy, treated and controlled HNC patients and to evaluate its effectiveness in preventing locoregional relapses and development of second primary tumours.

Materials and methods: Total 78 patients of treated head and neck cancers were randomly selected for intervention and control group. Patients in the intervention group (n = 38) received Varunadi Ghritha, 5gms twice daily for one year and followed up to two years. Patients in the control group (n = 40) were followed up at regular intervals. Immune parameters were assessed in the peripheral blood at base line and at the end of administration of the study compound.

Results: In the intervention group, mean percentage increase in CD3, CD19 and CD16 positive cells were significantly higher after the administration of the study compound compared to the control group indicating an immunomodulatory effect of the study compound. A non-significant improvement in disease control was observed in patients with advanced stage of disease in the intervention group.

Conclusion: Administration of Varunadi Ghritha resulted in an increase in T cell counts in patients with treated HNC.

Keywords: Ayurveda; head and neck cancer; immunomodulation; loco-regional control; second primary tumour.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Kaplan-Meier disease-free survival to recurrence by study group
See this image and copyright information in PMC

References

    1. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al., editors. Vol. 9. Lyon: IARC Press; 2007. Cancer Incidence in Five Continents.
    1. Cooper JS, Pajak TF, Rubin P, Tupchong L, Brady LW, Leibel SA, et al. Second malignancies in patients who have HNC incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys. 1989;17:449–56. - PubMed
    1. Strong MS, Incze J, Vaughan CW. Field cancerization in the aerodigestive tract-its etiology, manifestation and significance. J Otolaryngol. 1984;13:1–6. - PubMed
    1. de Vries N, van Zandwijk N, Pastorino U. Chemoprevention of head and neck and lung (pre) cancer. Recent Results Cancer Res. 1999;151:13–25. - PubMed
    1. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6:963–8. - PubMed